BR0207096A - Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 - Google Patents
Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3Info
- Publication number
- BR0207096A BR0207096A BR0207096-0A BR0207096A BR0207096A BR 0207096 A BR0207096 A BR 0207096A BR 0207096 A BR0207096 A BR 0207096A BR 0207096 A BR0207096 A BR 0207096A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- prophylaxis
- inhibition
- compounds
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"USO DE UM COMPOSTO, COMPOSTOS, FORMULAçãO FARMACêUTICA, E, MéTODO DE TRATAMENTO E/OU PROFILAXIA DE CONDIçõES ASSOCIADAS COM A INIBIçãO DE GLICOGêNIO SINTASE QUINASE-3". A presente invenção refere-se a um novo uso de derivados de pirimidina da fórmula (I), como uma base livre ou como um sal farmaceuticamente aceitável dos mesmos na manufatura de um medicamento no tratamento e/ou profilaxia de condições associadas com glicogênio sintase quinase-3. A presente invenção refere-se ainda a um método para o tratamento e/ou a profilaxia de condições associadas com glicogênio sintase quinase-3, compreendendo administrar a um mamífero, incluindo um ser humano necessitando de tal prevenção e/ou profilaxia, uma quantidade terapeuticamente efetiva dos referidos derivados de pirimidina, assim como a uma formulação farmacêutica para o referido uso. Em adição, a presente invenção refere-se a novos compostos adequados para a inibição de glicogênio sintase quinase-3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26990301P | 2001-02-20 | 2001-02-20 | |
PCT/SE2002/000270 WO2002066480A2 (en) | 2001-02-20 | 2002-02-18 | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0207096A true BR0207096A (pt) | 2004-01-20 |
Family
ID=23029104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0207096-0A BR0207096A (pt) | 2001-02-20 | 2002-02-18 | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
Country Status (17)
Country | Link |
---|---|
US (1) | US7078410B2 (pt) |
EP (1) | EP1423388B1 (pt) |
JP (1) | JP4309657B2 (pt) |
KR (1) | KR20030076688A (pt) |
CN (1) | CN100415744C (pt) |
AT (1) | ATE416175T1 (pt) |
BR (1) | BR0207096A (pt) |
CA (1) | CA2435177A1 (pt) |
DE (1) | DE60230160D1 (pt) |
ES (1) | ES2316546T3 (pt) |
HK (1) | HK1094697A1 (pt) |
IL (1) | IL156784A0 (pt) |
MX (1) | MXPA03007266A (pt) |
NO (1) | NO20033677L (pt) |
NZ (1) | NZ527009A (pt) |
WO (1) | WO2002066480A2 (pt) |
ZA (1) | ZA200306175B (pt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
AU2003208479A1 (en) | 2002-03-09 | 2003-09-22 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
JP4589122B2 (ja) * | 2002-12-03 | 2010-12-01 | 杏林製薬株式会社 | ホスホジエステラーゼ10a阻害剤 |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
KR20120062863A (ko) | 2003-07-30 | 2012-06-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물 |
US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
EP1799652A1 (en) * | 2004-10-13 | 2007-06-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
MX2007007272A (es) * | 2004-12-17 | 2007-07-11 | Astrazeneca Ab | 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk. |
US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
KR20080087070A (ko) * | 2005-05-20 | 2008-09-30 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1942897A1 (en) * | 2005-10-03 | 2008-07-16 | AstraZeneca AB | Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease |
AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
GB0520958D0 (en) | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
RU2008143179A (ru) * | 2006-03-31 | 2010-05-10 | Новартис АГ (CH) | Органические соединения |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
US8258129B2 (en) * | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
CN101547917A (zh) | 2006-12-08 | 2009-09-30 | 霍夫曼-拉罗奇有限公司 | 用作jnk调节剂的取代的嘧啶类化合物及它们的应用 |
CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
CN101679409B (zh) | 2006-12-22 | 2014-11-26 | Astex治疗学有限公司 | 双环杂环衍生化合物、其医药组合物和其用途 |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
NZ587589A (en) | 2008-02-15 | 2012-10-26 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
EP2306836B1 (en) * | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
UY32203A (es) * | 2008-10-29 | 2010-05-31 | Astrazeneca Ab | Amino pirimidinas y su uso en terapia |
CN101735211B (zh) * | 2008-11-04 | 2012-11-14 | 复旦大学 | 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途 |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
JP2012524063A (ja) | 2009-04-15 | 2012-10-11 | アストラゼネカ・アクチエボラーグ | アルツハイマー病などのグリコーゲンシンターゼキナーゼ3関連障害の治療に有用なイミダゾール置換ピリミジン |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
EP2440519A1 (en) | 2009-06-08 | 2012-04-18 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
MX2011013166A (es) | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina. |
NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
CN102391264A (zh) * | 2011-09-21 | 2012-03-28 | 河北九派制药有限公司 | 6-溴咪唑并[1,2-a]吡啶的制备方法 |
EP2671885A1 (en) * | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
US9738636B2 (en) | 2012-09-28 | 2017-08-22 | Vanderbilt University | Fused heterocyclic compounds as selective BMP inhibitors |
JP6412503B2 (ja) | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス, インコーポレイテッド | 置換逆ピリミジンBmi−1阻害剤 |
TWI692477B (zh) * | 2013-08-30 | 2020-05-01 | 美商Ptc治療公司 | 經取代嘧啶bmi-1抑制劑 |
EP3071553A4 (en) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
CN106362155A (zh) * | 2016-10-08 | 2017-02-01 | 无锡汉强医药科技有限公司 | Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用 |
WO2018108671A1 (en) | 2016-12-16 | 2018-06-21 | Basf Se | Pesticidal compounds |
US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
KR102249521B1 (ko) | 2018-11-14 | 2021-05-07 | 아이알링크 주식회사 | 스마트폰과 동기화되는 pc 인터페이스 장치 및 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG47583A1 (en) | 1986-01-13 | 1998-04-17 | American Cyanamid Co | 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines |
GB8901423D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
-
2002
- 2002-02-18 EP EP02712572A patent/EP1423388B1/en not_active Expired - Lifetime
- 2002-02-18 CN CNB028052528A patent/CN100415744C/zh not_active Expired - Fee Related
- 2002-02-18 WO PCT/SE2002/000270 patent/WO2002066480A2/en active Application Filing
- 2002-02-18 NZ NZ527009A patent/NZ527009A/en unknown
- 2002-02-18 BR BR0207096-0A patent/BR0207096A/pt not_active IP Right Cessation
- 2002-02-18 KR KR10-2003-7010875A patent/KR20030076688A/ko not_active Application Discontinuation
- 2002-02-18 MX MXPA03007266A patent/MXPA03007266A/es active IP Right Grant
- 2002-02-18 CA CA002435177A patent/CA2435177A1/en not_active Abandoned
- 2002-02-18 AT AT02712572T patent/ATE416175T1/de not_active IP Right Cessation
- 2002-02-18 IL IL15678402A patent/IL156784A0/xx unknown
- 2002-02-18 ES ES02712572T patent/ES2316546T3/es not_active Expired - Lifetime
- 2002-02-18 JP JP2002565994A patent/JP4309657B2/ja not_active Expired - Fee Related
- 2002-02-18 US US10/468,605 patent/US7078410B2/en not_active Expired - Fee Related
- 2002-02-18 DE DE60230160T patent/DE60230160D1/de not_active Expired - Lifetime
-
2003
- 2003-08-08 ZA ZA2003/06175A patent/ZA200306175B/en unknown
- 2003-08-19 NO NO20033677A patent/NO20033677L/no unknown
-
2007
- 2007-01-24 HK HK07100849.6A patent/HK1094697A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1423388B1 (en) | 2008-12-03 |
NO20033677L (no) | 2003-10-02 |
ATE416175T1 (de) | 2008-12-15 |
NZ527009A (en) | 2006-04-28 |
NO20033677D0 (no) | 2003-08-19 |
KR20030076688A (ko) | 2003-09-26 |
JP4309657B2 (ja) | 2009-08-05 |
CA2435177A1 (en) | 2002-08-29 |
HK1094697A1 (en) | 2007-04-04 |
CN100415744C (zh) | 2008-09-03 |
EP1423388A2 (en) | 2004-06-02 |
US20040106574A1 (en) | 2004-06-03 |
DE60230160D1 (de) | 2009-01-15 |
ES2316546T3 (es) | 2009-04-16 |
ZA200306175B (en) | 2005-01-26 |
CN1823064A (zh) | 2006-08-23 |
MXPA03007266A (es) | 2003-12-04 |
JP2004522777A (ja) | 2004-07-29 |
WO2002066480A3 (en) | 2004-04-01 |
IL156784A0 (en) | 2004-02-08 |
US7078410B2 (en) | 2006-07-18 |
WO2002066480A2 (en) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0207096A (pt) | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 | |
WO2001064035A3 (en) | Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof | |
WO2002085951A3 (en) | Water soluble, randomly substituted partial n-, partial o-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof | |
CA2527120A1 (en) | Stable aqueous solution of natamycin fungicide | |
NO20056239L (no) | Hyaluronsyre nanopartikler | |
AR030043A1 (es) | Sistema de agentes de hidrofobizado, polisiloxano, procedimiento para la obtencion de polisiloxanos, dispersiones acuosas, procedimiento para la obtencion de dispersiones acuosas, procedimiento para el hidrofobizado de sustratos, sustratos hidrofobizados y empleo del sistema de agentes de hidrofobiz | |
DE69924740D1 (de) | Klare wässrige lösungen enthaltend gallensäuren | |
RO117145B1 (ro) | Emulsie sau soluţie apoasă, mucoadezivă | |
WO2001056547A3 (en) | Preparation of aqueous clear solution dosage forms with bile acids | |
WO2003070181A3 (en) | Compositions and methods for preservation of food | |
CA2378424A1 (en) | Moxifloxacin formulation containing common salt | |
BR0309498A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos | |
CA2404083A1 (en) | Use of polyphosphate as a tooth erosion inhibitor in acidic compositions | |
BR0213569A (pt) | Supressão de viscosidade aquosa de poliacetal-poliéteres que se associam | |
WO2004011477A3 (en) | 6,11-4-carbon bridged ketolides | |
DE502007000308D1 (de) | Verwendung einer Behälterverschlussbeschichtungszusammensetzung, Behälterverschlussbeschichtung als antibakterielles Mittel, deren Herstellung und Aufbringung | |
CA2529441A1 (en) | Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas | |
WO2003101382A3 (en) | Compounds useful in the treatment of anthrax and inhibiting lethal factor | |
ES2026314A6 (es) | Procedimiento para obtener una composicion profilactica antimicrobiana oftalmica neonatal. | |
BR0207254A (pt) | Composto, composição farmacêutica, uso de pelo menos um composto, e, método para tratar distúrbios associados com um sistema imune perturbado | |
TW200519080A (en) | Agent containinf (2R)-2-propyloctanic acid as effective component | |
BRPI0416088A (pt) | composição, sistema, e método de tratar condições tais como calcificação vascular | |
EP1114826A3 (en) | Novel antibacterial and prokinetic macrolides | |
WO2002070404A3 (en) | Stabilised hypobromous acid solutions | |
WO2002067952A8 (en) | Prophylactic teat treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2055 DE 25/05/2010. |